Research Programme: nucleotide-competing reverse transcriptase inhibitors - Tibotec

Drug Profile

Research Programme: nucleotide-competing reverse transcriptase inhibitors - Tibotec

Alternative Names: NCRTI-1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator McGill University; Tibotec BVBA
  • Class Pyridones; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Belgium
  • 20 Feb 2008 This programme is still in active development
  • 22 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top